Bacil Pharma board approves fund raising up to ₹50 crores
Bacil Pharma Limited's board approved raising up to ₹50 crores through various modes including rights and preferential issues on June 26, 2026. The company authorized key officials to finalize the fund-raising structure and intermediaries, subject to regulatory approvals. The trading window remains closed for designated persons until 48 hours post-result declaration.
*this image is generated using AI for illustrative purposes only.
Bacil Pharma Limited's board has approved a proposal to raise funds up to ₹50 crores through one or more permissible modes, including a rights issue, preferential issue, and convertible securities. The decision, taken on June 26, 2026, aims to bolster the company's financial resources subject to statutory and regulatory approvals. The board authorized the Managing Director, Chief Financial Officer, and Company Secretary to evaluate options, appoint intermediaries, and finalize the issue structure.
The meeting, held at the company's registered office in Mumbai, commenced at 4 P.M. and concluded at 6 P.M. Directors considered various financial strategies in compliance with the Companies Act, 2013, and SEBI regulations, including the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The specific mode of fund raising, pricing, and terms will be determined based on market conditions and shareholder approvals where required.
In conjunction with the meeting outcome, the company had previously closed its trading window for all designated persons and their immediate relatives. This measure remains effective until 48 hours after the declaration of the board meeting's outcome, adhering to the company's Code of Conduct for Prevention of Insider Trading and the SEBI (Prohibition of Insider Trading) Regulations, 2015.
Mrs. Chaitali Kalpataru Shah, Director & CFO, signed the regulatory filing submitted to BSE Limited. The company will make requisite disclosures to the stock exchanges as and when definitive decisions are taken regarding the fund raising.
Key Agenda Items
| Agenda Item | Description |
|---|---|
| Fund Raising | Approval to raise up to ₹50 crores via rights issue, preferential issue, or convertible securities |
| Authorization | Managing Director, CFO, and Company Secretary authorized to finalize structure and intermediaries |
| Regulatory Compliance | Subject to Companies Act, 2013 and SEBI regulations |
| Trading Window | Closure for designated persons until 48 hours post-result declaration |
Historical Stock Returns for Bacil Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.90% | -3.44% | -5.16% | -14.61% | -0.80% | +460.60% |
What specific strategic initiatives or capital expenditures does Bacil Pharma plan to finance with the raised ₹50 crores?
How will the choice between a rights issue, preferential issue, or convertible securities impact existing shareholder dilution and debt levels?
What is the expected timeline for receiving statutory approvals and launching the fund-raising instrument?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
